Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

Andrea Gallamini, Caterina Patti, Simonetta Viviani, Andrea Rossi, Francesca Fiore, Francesco Di Raimondo, Maria Cantonetti, Caterina Stelitano, Tatyana Feldman, Paolo Gavarotti, Roberto Sorasio, Antonino Mulè, Monica Leone, Alessandro Rambaldi, Alberto Biggi, Sally Barrington, Federico Fallanca, Umberto Ficola, Stéphane Chauvie, Alessandro Massimo Gianni

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Interim 2-[18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography performed after two chemotherapy cycles (PET-2) is the most reliable predictor of treatment outcome in ABVD-treated Hodgkin Lymphoma (HL) patients. We retrospectively analysed the treatment outcome of a therapeutic strategy based on PET-2 results: positive patients switched to BEACOPP, while negative patients continued with ABVD. Between January 2006 and December 2007, 219 newly diagnosed HL patients admitted to nine centres were enrolled; 54 patients, unfit to receive this treatment were excluded from the analysis. PET-2 scans were reviewed by a central panel of nuclear medicine experts, according to the Deauville score (Meignan, 2009). After a median follow up of 34months (12-52) the 2-year failure free survival (FFS) and overall survival for the entire cohort of 165 patients were 88% and 98%; the FFS was 65% for PET-2 positive and 92% for PET-2 negative patients. For 154 patients in which treatment was correctly given according to PET-2 review, the 2-year FFS was 91%: 62% for PET-2 positive and 95% for PET-2 negative patients. Conclusions: this strategy, with BEACOPP intensification only in PET-2 positive patients, showed better results than ABVD-treated historic controls, sparing BEACOPP toxicity to the majority of patients (Clinical Trials.gov Identifier NCT00877747).

Original languageEnglish
Pages (from-to)551-560
Number of pages10
JournalBritish Journal of Haematology
Volume152
Issue number5
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Hodgkin Disease
Drug Therapy
Survival
Positron-Emission Tomography
Nuclear Medicine
Fluorodeoxyglucose F18
Therapeutics
Clinical Trials

Keywords

  • ABVD
  • BEACOPP
  • Hodgkin lymphoma
  • Positron emission tomography
  • Review panel

ASJC Scopus subject areas

  • Hematology

Cite this

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. / Gallamini, Andrea; Patti, Caterina; Viviani, Simonetta; Rossi, Andrea; Fiore, Francesca; Di Raimondo, Francesco; Cantonetti, Maria; Stelitano, Caterina; Feldman, Tatyana; Gavarotti, Paolo; Sorasio, Roberto; Mulè, Antonino; Leone, Monica; Rambaldi, Alessandro; Biggi, Alberto; Barrington, Sally; Fallanca, Federico; Ficola, Umberto; Chauvie, Stéphane; Gianni, Alessandro Massimo.

In: British Journal of Haematology, Vol. 152, No. 5, 03.2011, p. 551-560.

Research output: Contribution to journalArticle

Gallamini, A, Patti, C, Viviani, S, Rossi, A, Fiore, F, Di Raimondo, F, Cantonetti, M, Stelitano, C, Feldman, T, Gavarotti, P, Sorasio, R, Mulè, A, Leone, M, Rambaldi, A, Biggi, A, Barrington, S, Fallanca, F, Ficola, U, Chauvie, S & Gianni, AM 2011, 'Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses', British Journal of Haematology, vol. 152, no. 5, pp. 551-560. https://doi.org/10.1111/j.1365-2141.2010.08485.x
Gallamini, Andrea ; Patti, Caterina ; Viviani, Simonetta ; Rossi, Andrea ; Fiore, Francesca ; Di Raimondo, Francesco ; Cantonetti, Maria ; Stelitano, Caterina ; Feldman, Tatyana ; Gavarotti, Paolo ; Sorasio, Roberto ; Mulè, Antonino ; Leone, Monica ; Rambaldi, Alessandro ; Biggi, Alberto ; Barrington, Sally ; Fallanca, Federico ; Ficola, Umberto ; Chauvie, Stéphane ; Gianni, Alessandro Massimo. / Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. In: British Journal of Haematology. 2011 ; Vol. 152, No. 5. pp. 551-560.
@article{7375b9a88a5e4bfa9ff52a190dc1aac2,
title = "Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses",
abstract = "Interim 2-[18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography performed after two chemotherapy cycles (PET-2) is the most reliable predictor of treatment outcome in ABVD-treated Hodgkin Lymphoma (HL) patients. We retrospectively analysed the treatment outcome of a therapeutic strategy based on PET-2 results: positive patients switched to BEACOPP, while negative patients continued with ABVD. Between January 2006 and December 2007, 219 newly diagnosed HL patients admitted to nine centres were enrolled; 54 patients, unfit to receive this treatment were excluded from the analysis. PET-2 scans were reviewed by a central panel of nuclear medicine experts, according to the Deauville score (Meignan, 2009). After a median follow up of 34months (12-52) the 2-year failure free survival (FFS) and overall survival for the entire cohort of 165 patients were 88{\%} and 98{\%}; the FFS was 65{\%} for PET-2 positive and 92{\%} for PET-2 negative patients. For 154 patients in which treatment was correctly given according to PET-2 review, the 2-year FFS was 91{\%}: 62{\%} for PET-2 positive and 95{\%} for PET-2 negative patients. Conclusions: this strategy, with BEACOPP intensification only in PET-2 positive patients, showed better results than ABVD-treated historic controls, sparing BEACOPP toxicity to the majority of patients (Clinical Trials.gov Identifier NCT00877747).",
keywords = "ABVD, BEACOPP, Hodgkin lymphoma, Positron emission tomography, Review panel",
author = "Andrea Gallamini and Caterina Patti and Simonetta Viviani and Andrea Rossi and Francesca Fiore and {Di Raimondo}, Francesco and Maria Cantonetti and Caterina Stelitano and Tatyana Feldman and Paolo Gavarotti and Roberto Sorasio and Antonino Mul{\`e} and Monica Leone and Alessandro Rambaldi and Alberto Biggi and Sally Barrington and Federico Fallanca and Umberto Ficola and St{\'e}phane Chauvie and Gianni, {Alessandro Massimo}",
year = "2011",
month = "3",
doi = "10.1111/j.1365-2141.2010.08485.x",
language = "English",
volume = "152",
pages = "551--560",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

AU - Gallamini, Andrea

AU - Patti, Caterina

AU - Viviani, Simonetta

AU - Rossi, Andrea

AU - Fiore, Francesca

AU - Di Raimondo, Francesco

AU - Cantonetti, Maria

AU - Stelitano, Caterina

AU - Feldman, Tatyana

AU - Gavarotti, Paolo

AU - Sorasio, Roberto

AU - Mulè, Antonino

AU - Leone, Monica

AU - Rambaldi, Alessandro

AU - Biggi, Alberto

AU - Barrington, Sally

AU - Fallanca, Federico

AU - Ficola, Umberto

AU - Chauvie, Stéphane

AU - Gianni, Alessandro Massimo

PY - 2011/3

Y1 - 2011/3

N2 - Interim 2-[18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography performed after two chemotherapy cycles (PET-2) is the most reliable predictor of treatment outcome in ABVD-treated Hodgkin Lymphoma (HL) patients. We retrospectively analysed the treatment outcome of a therapeutic strategy based on PET-2 results: positive patients switched to BEACOPP, while negative patients continued with ABVD. Between January 2006 and December 2007, 219 newly diagnosed HL patients admitted to nine centres were enrolled; 54 patients, unfit to receive this treatment were excluded from the analysis. PET-2 scans were reviewed by a central panel of nuclear medicine experts, according to the Deauville score (Meignan, 2009). After a median follow up of 34months (12-52) the 2-year failure free survival (FFS) and overall survival for the entire cohort of 165 patients were 88% and 98%; the FFS was 65% for PET-2 positive and 92% for PET-2 negative patients. For 154 patients in which treatment was correctly given according to PET-2 review, the 2-year FFS was 91%: 62% for PET-2 positive and 95% for PET-2 negative patients. Conclusions: this strategy, with BEACOPP intensification only in PET-2 positive patients, showed better results than ABVD-treated historic controls, sparing BEACOPP toxicity to the majority of patients (Clinical Trials.gov Identifier NCT00877747).

AB - Interim 2-[18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography performed after two chemotherapy cycles (PET-2) is the most reliable predictor of treatment outcome in ABVD-treated Hodgkin Lymphoma (HL) patients. We retrospectively analysed the treatment outcome of a therapeutic strategy based on PET-2 results: positive patients switched to BEACOPP, while negative patients continued with ABVD. Between January 2006 and December 2007, 219 newly diagnosed HL patients admitted to nine centres were enrolled; 54 patients, unfit to receive this treatment were excluded from the analysis. PET-2 scans were reviewed by a central panel of nuclear medicine experts, according to the Deauville score (Meignan, 2009). After a median follow up of 34months (12-52) the 2-year failure free survival (FFS) and overall survival for the entire cohort of 165 patients were 88% and 98%; the FFS was 65% for PET-2 positive and 92% for PET-2 negative patients. For 154 patients in which treatment was correctly given according to PET-2 review, the 2-year FFS was 91%: 62% for PET-2 positive and 95% for PET-2 negative patients. Conclusions: this strategy, with BEACOPP intensification only in PET-2 positive patients, showed better results than ABVD-treated historic controls, sparing BEACOPP toxicity to the majority of patients (Clinical Trials.gov Identifier NCT00877747).

KW - ABVD

KW - BEACOPP

KW - Hodgkin lymphoma

KW - Positron emission tomography

KW - Review panel

UR - http://www.scopus.com/inward/record.url?scp=79951524764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951524764&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08485.x

DO - 10.1111/j.1365-2141.2010.08485.x

M3 - Article

C2 - 21166786

AN - SCOPUS:79951524764

VL - 152

SP - 551

EP - 560

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -